Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Cardiologia - SBC
2015
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0066-782X2015002100139 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0066-782X20150021001392016-06-13Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel MutationBaptista,AnaMagalhães,PedroLeão,SílviaCarvalho,SofiaMateus,PedroMoreira,Ilídio Fabry disease / complications Hypertrophy, left ventricular Alpha-Galactosidase / genetics Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).info:eu-repo/semantics/openAccessSociedade Brasileira de Cardiologia - SBCArquivos Brasileiros de Cardiologia v.105 n.2 20152015-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139en10.5935/abc.20150090 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Baptista,Ana Magalhães,Pedro Leão,Sílvia Carvalho,Sofia Mateus,Pedro Moreira,Ilídio |
spellingShingle |
Baptista,Ana Magalhães,Pedro Leão,Sílvia Carvalho,Sofia Mateus,Pedro Moreira,Ilídio Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
author_facet |
Baptista,Ana Magalhães,Pedro Leão,Sílvia Carvalho,Sofia Mateus,Pedro Moreira,Ilídio |
author_sort |
Baptista,Ana |
title |
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
title_short |
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
title_full |
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
title_fullStr |
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
title_full_unstemmed |
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation |
title_sort |
screening for fabry disease in left ventricular hypertrophy: documentation of a novel mutation |
description |
Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5). |
publisher |
Sociedade Brasileira de Cardiologia - SBC |
publishDate |
2015 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139 |
work_keys_str_mv |
AT baptistaana screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation AT magalhaespedro screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation AT leaosilvia screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation AT carvalhosofia screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation AT mateuspedro screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation AT moreirailidio screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation |
_version_ |
1756381981422125056 |